PD-L1 expression, HER2 positive, EBV infection, D-MMR/MSI-H, and TMB-high are well-known biomarkers to predict response from PD-1 inhibitor single agents in the third-line setting [43]; however, their value in predicting response to immunochemotherapy is unknown. Here, ERBB2 is linked to Epstein-Barr virus infection.